Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.

abstract：:Cancer often leads to the activation of coagulation, manifesting as disseminated intravascular coagulation (DIC) in its most extreme form. DIC is characterized by systemic intravascular coagulation activation (leading to deposition of intravascular platelets and fibrin) and simultaneous consumption of coagulation prot...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2019-06-01 00:00:00

abstract：:Current concepts of etiology and pathophysiology resulting in disseminated intravascular coagulation (DIC) form the basis of treatment of this hemostatic disorder. Due to the heterogeneous triggering diseases and different kinds of DIC, clinical symptoms such as predominant bleeding, thromboembolic complications or or...

journal_title：Seminars in thrombosis and hemostasis

authors： Riewald M,Riess H

更新日期：1998-01-01 00:00:00

abstract：:Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissol...

journal_title：Seminars in thrombosis and hemostasis

authors： Yamamoto K,Takeshita K,Saito H

更新日期：2014-09-01 00:00:00

abstract：:From injury through healing, thrombin has several important functions in blood clotting, subsequent clot lysis, and tissue repair. These include edema, inflammation, cell recruitment, cellular releases, transformations, mitogenesis, and angiogenesis. Thrombin also participates in disease states, such as venous thrombo...

journal_title：Seminars in thrombosis and hemostasis

authors： Fenton JW 2nd,Ofosu FA,Brezniak DV,Hassouna HI

更新日期：1998-01-01 00:00:00

abstract：:Sulfated glycosaminoglycans (GAGs) are amenable to a number of chemical modifications that modulate their biological activity. N-sulfate groups can be exposed and N-acylated (usually N-acetylated), specific O-sulfate groups can be removed, and free hydroxyl groups (either preexisting in the original GAG or exposed by ...

journal_title：Seminars in thrombosis and hemostasis

authors： Casu B,Naggi A,Torri G

更新日期：2002-08-01 00:00:00

abstract：:Current guidelines for venous thromboembolism (VTE) primary prophylaxis are based on randomized clinical trials that exclude subjects at a potentially high bleeding risk. Thus no specific recommendation/algorithm for pharmacological prophylaxis in patients with thrombocytopenia and/or platelet dysfunction is available...

journal_title：Seminars in thrombosis and hemostasis

authors： Tufano A,Guida A,Di Minno MN,Prisco D,Cerbone AM,Di Minno G

更新日期：2011-04-01 00:00:00

abstract：:In the past two decades, major improvements in antibiotics and other elements of supportive care have decreased the number and severity of complications of hematopoietic stem cell transplantation (HSCT). Despite these improvements, many subpopulations of transplant patients still have a significant morbidity and morta...

journal_title：Seminars in thrombosis and hemostasis

authors： Haire WD

更新日期：1999-01-01 00:00:00

abstract：:Three commercial prothrombin complex concentrates (PCC) were compared in vitro. Differences in the activities or contents, respectively, of the PCC factors FII, FVII, FIX, FX and the proteins C, S, and Z (antigen) in particular were found. Global tests of activated factors did not reveal marked differences between the...

journal_title：Seminars in thrombosis and hemostasis

authors： Römisch J,Bonik K,Müller HG

更新日期：1998-01-01 00:00:00

abstract：:Platelet-type von Willebrand disease (PT-VWD) and type 2B von Willebrand disease (2B-VWD) are rare bleeding disorders characterized by increased ristocetin-induced platelet aggregation (RIPA) at low concentrations of ristocetin. Diagnosis of either condition is not easy and the differential diagnosis between the two e...

journal_title：Seminars in thrombosis and hemostasis

authors： Woods AI,Sanchez-Luceros A,Bermejo E,Paiva J,Alberto MF,Grosso SH,Kempfer AC,Lazzari MA

更新日期：2014-03-01 00:00:00

abstract：:The beta2-glycoprotein I (beta2-GPI) is known for its procoagulant as well as anticoagulant properties. The influence of beta2-GPI on tissue factor (TF) activity was investigated by chromogenic assays for both factor Xa generation and factor VIIa activity. When 1.36 mg/mL beta2-GPI was added to phospholipids prior to ...

journal_title：Seminars in thrombosis and hemostasis

authors： Ieko M,Yasukouchi T,Sawada KI,Koike T

更新日期：1998-01-01 00:00:00

abstract：:Patients receiving heparin are at risk of developing heparin-induced thrombocytopenia (HIT). Whereas in HIT I only reversible mild thrombocytopenia occurs within the first days of heparin treatment, HIT II may lead to potentially life-threatening thromboembolic events. Pediatric patients suffering from HIT II have bee...

journal_title：Seminars in thrombosis and hemostasis

authors： Severin T,Zieger B,Sutor AH

更新日期：2002-10-01 00:00:00

abstract：:The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

journal_title：Seminars in thrombosis and hemostasis

authors： Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

更新日期：1997-01-01 00:00:00

abstract：:Several LMWHs are currently available for commercial use. The development status of each of these products in the area of prophylaxis, therapeutics, and other indications is given in Table 4. Enoxaparin and Fraxiparin appear to be the most developed LMWHs in both the surgical and medical areas. Many well-designed clin...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Hoppensteadt D,Borris LC,Lassen MR

更新日期：1991-01-01 00:00:00

abstract：:The purpose of this article is to review the use of blood products and hemostatic agents in the management of coagulopathy at the time of postpartum hemorrhage. Blood product administration strategies are broadly reviewed, including the role of the blood bank, the role of massive transfusion protocols, the role of lab...

journal_title：Seminars in thrombosis and hemostasis

authors： James AH,Grotegut C,Ahmadzia H,Peterson-Layne C,Lockhart E

更新日期：2016-10-01 00:00:00

abstract：:Thrombotic diseases, as potentially induced by blood clots or vascular embolization, frequently occur with high rates of mortalities worldwide. Current drug thrombolysis, a primary clinical therapy, may increase fatal risk of hemorrhage when thrombolysis agents become systemically distributed. Given current thrombolys...

journal_title：Seminars in thrombosis and hemostasis

authors： Qu S,Ding X

更新日期：2020-07-01 00:00:00

abstract：:Thrombosis is characterized by the formation of in vivo blood clots that are localized within arterial or venous blood vessels. These thrombi form beyond the need for physiologically healthy hemostatic responses and can lead to significant medical issues for affected individuals. Unfortunately, the existing standard-o...

journal_title：Seminars in thrombosis and hemostasis

authors： Palazzolo JS,Westein E,Hagemeyer CE,Wang TY

更新日期：2020-07-01 00:00:00

abstract：:Polycystic ovarian syndrome (PCOS) affects 12 to 19% of women and has reproductive and metabolic features (endothelial dysfunction, increased diabetes, and cardiovascular risk factors). It also appears to have altered coagulation and fibrinolysis with a prothrombotic state with epidemiological evidence of increased ve...

journal_title：Seminars in thrombosis and hemostasis

authors： Burchall GF,Piva TJ,Linden MD,Gibson-Helm ME,Ranasinha S,Teede HJ

更新日期：2016-02-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL), once highly fatal, has emerged as the most curable subtype of acute myeloid leukemia in adults. Cure is now expected in approximately 70 to 90% of patients when treatment includes all- TRANS retinoic acid (ATRA) combined with anthracycline-based chemotherapy. Early mortality most of...

journal_title：Seminars in thrombosis and hemostasis

authors： Tallman MS,Abutalib SA,Altman JK

更新日期：2007-06-01 00:00:00

abstract：:The articular problems of patients with hemophilia begin in infancy when minor injuries result in hemarthroses. Early continuous prophylaxis (from cradle to college) is of paramount importance because the immature skeleton is very sensitive to the complications of hemophilia; severe structural deficiencies may develop...

journal_title：Seminars in thrombosis and hemostasis

authors： Rodriguez-Merchan EC,Heim M

更新日期：2005-11-01 00:00:00

abstract：:A simple RIA method for B beta 15-42 RPs has been evaluated in our laboratory to investigate experimental and clinical fibrinolytic states. The assay utilizes bentonite precipitation to remove cross-reacting fibrinogen. Due to the heterogeneity in molecular weights of the B beta RPs, the results are expressed as nanog...

journal_title：Seminars in thrombosis and hemostasis

authors： Walenga JM,Fareed J,Mariani G,Messmore HL Jr,Bick RL,Emanuele RM

更新日期：1984-10-01 00:00:00

abstract：INTRODUCTION:The aim of this study was to evaluate the genetic variability of selected single nucleotide polymorphisms (SNPs) within GAS6 and PEAR1 genes and explore the association between selected SNPs and risk for fetal loss in women with sticky platelet syndrome (SPS). MATERIALS AND METHODS:We examined 23 female p...

journal_title：Seminars in thrombosis and hemostasis

authors： Sokol J,Biringer K,Skerenova M,Stasko J,Kubisz P,Danko J

更新日期：2015-04-01 00:00:00

abstract：:CD34 (+) progenitor cells are a promising source of regeneration in atherosclerosis or ischemic heart disease. However, as recently published, CD34(+) progenitor cells have the potential to differentiate not only into endothelial cells but also into foam cells upon interaction with platelets. The mechanism of platelet...

journal_title：Seminars in thrombosis and hemostasis

authors： Seizer P,Schiemann S,Merz T,Daub K,Bigalke B,Stellos K,Müller I,Stöckle C,Müller K,Gawaz M,May AE

更新日期：2010-03-01 00:00:00

abstract：:A series of sulfated bis-lactobionic acid amides was prepared. The compounds comprise highly charged poly-anions of very low molecular weight. Usually, the compounds contain 16 sulfate groups per molecule and are homogeneous, monodisperse substances. The molecular weights range from 2388 to 2514. The compounds were ev...

journal_title：Seminars in thrombosis and hemostasis

authors： Klauser RJ,Meinetsberger E,Raake W

更新日期：1991-01-01 00:00:00

abstract：:The long-term success rate of coronary angioplasty is only 50 to 70% due to restenosis. The pathophysiologic mechanism of this event is mainly mediated by smooth muscle cell proliferation. To some extent, it can be inhibited by heparin. The introduction of LMWHs allows for prophylaxis against restenosis on an outpatie...

journal_title：Seminars in thrombosis and hemostasis

authors： Lojewski B,Bacher P,Iqbal O,Walenga JM,Hoppensteadt DA,Leya F,Fareed J

更新日期：1993-01-01 00:00:00

abstract：:Neonatal hemostasis differs qualitatively, but in particular quantitatively, from hemostasis in older children and adults. Nevertheless, hemostasis in healthy neonates is functionally stable with no tendency to bleeding or thrombotic complications. In sick neonates, however, risk factors may disrupt this equilibrium a...

journal_title：Seminars in thrombosis and hemostasis

authors： van Ommen CH,Sol JJ

更新日期：2016-10-01 00:00:00

abstract：:The mechanism of thrombosis in patients with antiphospholipid syndrome is not clear. To investigate it, we examined the effect of monoclonal anticardiolipin (aCL) antibodies and beta2-glycoprotein I (beta2-GPI), which is required for formation of the aCL epitopes, on activated protein C (APC) and on fibrinolytic activ...

journal_title：Seminars in thrombosis and hemostasis

authors： Ieko M,Sawada KI,Koike T,Notoya A,Mukai M,Kohno M,Wada N,Itoh T,Yoshioka N

更新日期：1999-01-01 00:00:00

abstract：:The age of the thrombus is probably a very important determinant of the outcome of thrombolysis. The clinical potential for rapidly dissolving thrombi by thrombolytic therapy is considerable because restoration of the blood flow can rescue the jeopardized district served by the occluded vessel such as for myocardial i...

journal_title：Seminars in thrombosis and hemostasis

authors： Niada R,Porta R,Pescador R,Mantovani M,Prino G

更新日期：1989-10-01 00:00:00

abstract：:Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement ...

journal_title：Seminars in thrombosis and hemostasis

authors： Persson E,Olsen OH,Bjørn SE,Ezban M

更新日期：2012-04-01 00:00:00

abstract：:As the understanding of the genetic basis of the inherited thrombophilias has increased over recent years, their routine diagnostic genetic analysis has also matured. This review considers methods used to test for the factor V (F5) Leiden mutation and prothrombin 20210A (F2 c.*97G>A) allele, and analysis of the SERPIN...

journal_title：Seminars in thrombosis and hemostasis

authors： Cooper PC,Goodeve AC,Beauchamp NJ

更新日期：2012-09-01 00:00:00

abstract：:The delicate biochemistry of coagulation and anticoagulation is greatly affected by deviations from the optimal temperature required for the interactions between various coagulation enzymes, cellular receptors, and intracellular mechanisms. Hyperthermia will lead to a prothrombotic state and, if sufficiently severe su...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2018-10-01 00:00:00